Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Published:2017-12 Issue:12 Volume:18 Page:1652-1664
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ferolla Piero,Brizzi Maria Pia,Meyer Tim,Mansoor Wasat,Mazieres Julien,Do Cao Christine,Léna Hervé,Berruti Alfredo,Damiano Vincenzo,Buikhuisen Wieneke,Grønbæk Henning,Lombard-Bohas Catherine,Grohé Christian,Minotti Vincenzo,Tiseo Marcello,De Castro Javier,Reed Nicholas,Gislimberti Gabriella,Singh Neha,Stankovic Miona,Öberg Kjell,Baudin Eric

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J Clin Oncol,2008

2. WHO classification of tumours of the lung, pleura, thymus and heart,2015

3. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoid;Caplin;Ann Oncol,2015

4. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site;Pavel;Neuroendocrinology,2016

5. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study;Yao;Lancet,2016

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors;Current Problems in Cancer;2024-01

2. Lung Carcinoids: A Comprehensive Review for Clinicians;Cancers;2023-11-16

3. Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study;Cancers;2023-11-12

4. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management;Journal of Clinical Medicine;2023-08-05

5. Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors – Experiences from a tertiary referral center;Journal of Neuroendocrinology;2023-07-23